Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of LILR antibody specificities and development of LILRA3-specific antibodies.

Frontiers in immunology·2026

Same author

Expression of Glycoprotein B (gB) Correlates With Poor Prognosis in Nasopharyngeal Carcinoma.

Cancer science·2026

Same author

Induction of antigen-specific regulatory T cells by engineered extracellular vesicles.

Drug delivery·2025

Same author

Probing Nanomechanics by Direct Indentation Using Nanoendoscopy-AFM Reveals the Nuclear Elasticity Transition in Cancer Cells.

ACS applied nano materials·2025

Same author

Selective expansion and differentiation of antigen-specific CD4<sup>+</sup> T-helper cells by engineered extracellular vesicles.

Drug delivery·2025

Same author

Direct delivery of immune modulators to tumour-infiltrating lymphocytes using engineered extracellular vesicles.

Journal of extracellular vesicles·2025

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Engineered Extracellular Vesicles as Programmable Immune Interfaces: Surface and Cargo Engineering for Cancer

Tomoyoshi Yamano^1,2, Rikinari Hanayama^1,2

¹Department of Immunology, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.

|July 13, 2026

Summary

Engineered extracellular vesicles (EVs) act as programmable immune interfaces for targeted therapies. These nanoscale platforms offer versatile strategies for cancer immunotherapy and immune regulation, advancing next-generation therapeutics.

Keywords:

EV engineering MSC-EV cancer immunotherapy cargo loading clinical translation extracellular vesicles immune regulation surface display

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: Jul 14, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

Immunology
Nanotechnology
Biotechnology

Background:

Extracellular vesicles (EVs) are key mediators of intercellular communication via transferred biomolecules.
Their inherent properties like biocompatibility and targeted delivery make them promising therapeutic platforms.
Engineering EVs transforms them into programmable interfaces for modulating immune responses.

Purpose of the Study:

To review recent advancements in engineering extracellular vesicles (EVs) for immune regulation.
To highlight strategies for surface display, cellular targeting, and cargo loading in engineered EVs.
To explore the application of engineered EVs in cancer immunotherapy and autoimmune diseases.

Main Methods:

Surface display engineering for antigen specificity and cell targeting.
Cargo loading strategies for delivering therapeutic molecules (e.g., RNA, cytotoxic agents).
Development of EVs for specific immune modulation (e.g., immunostimulatory or tolerogenic signals).

Main Results:

Engineered EVs can integrate multiple functions: antigen specificity, target recognition, and therapeutic delivery.
Applications include cancer immunotherapy, immune suppression, and antigen-specific tolerance induction.
Specific examples include antigen-presenting EVs, RNA-loaded EVs, and MSC-derived EVs.

Conclusions:

Programmable EV immune interfaces represent a versatile foundation for next-generation immunotherapies.
Engineered EVs can be designed to direct immune responses in a context-dependent manner.
Clinical translation requires addressing manufacturing, characterization, safety, and regulatory challenges.